Are you interested in possibly participating in a clinical trial for Warm Autoimmune Hemolytic Anemia?
What is this study about?
This clinical study is being conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and effects on warm autoimmune hemolytic anemia (WAIHA) disease activity markers of a new investigational drug candidate.
What is involved in study participation?
All patients who meet eligibility criteria and are enrolled in the study will receive the study drug.
Enrolled patients will be followed intermittently for up to 16 weeks to assess the safety, tolerability, levels of study drug in your blood and effects of the study drug on WAIHA disease.
Who can participate in the study?
An individual may be able to take part in the study if he/she*:
Is 18 years or older
Has been diagnosed with Warm Autoimmune Hemolytic Anemia
